C
49.13
1.07 (2.23%)
| Previous Close | 48.06 |
| Open | 48.54 |
| Volume | 147,799 |
| Avg. Volume (3M) | 1,595,001 |
| Market Cap | 4,662,035,968 |
| Price / Sales | 2.91 |
| Price / Book | 4.24 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 143.00 (JMP Securities, 191.07%) | Buy |
| Median | 82.00 (66.90%) | |
| Low | 40.00 (Goldman Sachs, -18.58%) | Hold |
| Average | 82.13 (67.17%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 42.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 07 Nov 2025 | 108.00 (119.82%) | Buy | 40.00 |
| Oppenheimer | 30 Sep 2025 | 87.00 (77.08%) | Buy | 41.65 |
| Leerink Partners | 29 Sep 2025 | 88.00 (79.12%) | Buy | 43.51 |
| Morgan Stanley | 29 Sep 2025 | 77.00 (56.73%) | Buy | 43.51 |
| Baird | 26 Sep 2025 | 62.00 (26.20%) | Buy | 45.91 |
| Goldman Sachs | 26 Sep 2025 | 40.00 (-18.58%) | Hold | 45.91 |
| JMP Securities | 26 Sep 2025 | 143.00 (191.06%) | Buy | 45.91 |
| JP Morgan | 24 Sep 2025 | 52.00 (5.84%) | Buy | 35.18 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PIZZUTI DANA | - | 45.25 | -5,000 | -226,250 |
| Aggregate Net Quantity | -5,000 | |||
| Aggregate Net Value ($) | -226,250 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 45.25 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PIZZUTI DANA | Officer | 01 Dec 2025 | Automatic sell (-) | 5,000 | 45.25 | 226,250 |
| PIZZUTI DANA | Officer | 01 Dec 2025 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |